Venmax drugs & pharmaceuticals Limited has filed its quarterly statement confirming no deviation or variation in the utilization of funds raised through its preferential issue for the quarter ended December 31, 2025. The statement was submitted to BSE Limited on February 7, 2026, in compliance with Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Fund Raising Details

The company raised funds through the issue of fully convertible equity warrants on a preferential basis. The fund raising exercise was completed on March 20, 2025, with shareholder approval obtained on February 6, 2025.

Fund Allocation and Utilization

The proceeds from the preferential issue were allocated for two primary objectives. The company has provided a detailed breakdown of the original allocation and actual utilization as of December 31, 2025.

Compliance and Governance

The statement was duly reviewed by the Audit Committee in its meeting held on February 7, 2026. The company confirmed that there is no deviation or variation in the use of proceeds from the objects stated in the EGM Notice for Preferential Issue. No monitoring agency has been appointed for overseeing the fund utilization.

Key Compliance Highlights:

• Statement filed pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015
• Audit Committee review completed on February 7, 2026
• No auditor comments reported
• No deviation or variation confirmed for the quarter

Corporate Information

The statement was signed by Venkata Rao Sadhanala, Whole Time Director (DIN: 02906370), on behalf of Venmax Drugs & Pharmaceuticals Limited. The company is registered in Telangana with CIN: L24230TG1988PLC009102 and has its registered office at Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009.

The quarterly compliance filing demonstrates the company's adherence to regulatory requirements and transparent disclosure of fund utilization to stakeholders and regulatory authorities.

Venmax drugs & pharmaceuticals Limited has completed the allotment of 7,75,000 equity shares through warrant conversion on January 21, 2026. The Board of Directors approved the conversion after three warrant holders exercised their conversion rights, originally allotted warrants on March 20, 2025.

Warrant Conversion Details

The allotment involved conversion of warrants at an issue price of ₹20 per share, comprising face value of ₹10 and premium of ₹10 each. The warrant holders paid the balance exercise price of ₹15 per warrant, representing 75% of the total warrant exercise price, aggregating to ₹1,16,25,000.

Allottee Breakdown

All three warrant holders who exercised conversion rights belong to the non-promoter category. The conversion was executed on a 1:1 basis, with each warrant converting into one equity share.

Impact on Share Capital

Following the allotment, the company's paid-up capital has increased substantially. The new capital structure reflects the successful conversion of a portion of the outstanding warrants issued under the preferential allotment scheme.

Outstanding Warrants

The conversion represents partial utilization of the total warrants issued. Out of the original 1,00,25,000 warrants allotted in March 2025, a significant portion remains available for future conversion by other warrant holders.

The allotment was conducted under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, following preferential allotment norms. The Board meeting for approving the conversion commenced at 4:00 PM and concluded at 5:00 PM on January 21, 2026.